| Market Capitalization (Millions $) |
1,774 |
| Shares
Outstanding (Millions) |
89 |
| Employees |
298 |
| Revenues (TTM) (Millions $) |
252 |
| Net Income (TTM) (Millions $) |
-221 |
| Cash Flow (TTM) (Millions $) |
22 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for a range of cancer indications. The company was founded in 2005 and is headquartered in Waltham, Massachusetts, USA.
Syndax Pharmaceuticals' lead candidate, Entinostat, is a selective histone deacetylase (HDAC) inhibitor that has shown promising results in clinical trials for the treatment of advanced breast cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Entinostat works by inhibiting HDAC activity, which allows for the epigenetic reprogramming of cancer cells and the induction of tumor cell death. Syndax Pharmaceuticals is also developing a pipeline of other potentially groundbreaking therapies for cancer, including SNDX-6352, which is a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) and has demonstrated strong anti-tumor activity in preclinical models.
Syndax Pharmaceuticals is committed to developing innovative treatments for cancer patients and has a strong team of scientists, researchers, and executives who are dedicated to making a difference in the lives of patients. The company has received numerous awards and recognitions for its cutting-edge work in the field of oncology, including being named a "Best Place to Work" by the Boston Business Journal and a "Top 10 Breakthrough Technology" by MIT Technology Review.
In addition to its clinical development programs, Syndax Pharmaceuticals is also focused on building strategic partnerships with other companies in the biopharmaceutical industry. The company has established collaborations with several leading academic institutions and pharmaceutical companies, including Merck, Pfizer, and AstraZeneca, to advance the development of its pipeline of therapeutic candidates.
Overall, Syndax Pharmaceuticals is a dynamic and innovative company that is poised to make a significant impact in the field of oncology. With a strong track record of scientific and clinical success, a talented team of professionals, and a commitment to advancing the cause of cancer research and treatment, Syndax Pharmaceuticals is well-positioned to continue making important contributions to the fight against cancer for years to come.
Company Address: 730 Third Avenue New York 10017 NY
Company Phone Number: 419-1400 Stock Exchange / Ticker: NASDAQ SNDX
|
1.36% 
142.36 %